Celltrion reports 2.54 trillion won half-year revenue
The company recorded 2.54 trillion won in consolidated revenue for the first half of 2026.
The global biotechnology firm Celltrion reported consolidated revenue of 2.54 trillion won for the first half of 2026. This represents a decrease from the 4.16 trillion won recorded during the same period in the previous year.
Biopharmaceutical products and services, primarily CT-P13 biosimilars and others, generated 2.4 trillion won in revenue. Chemical pharmaceuticals, including Godex and other items, contributed 142 billion won to the total. The company currently utilizes a direct sales system across Europe, Asia, Central and South America, the United States, and Canada to maintain price competitiveness.
Operating results for the first half of 2026 met the company's previously stated goals. The company said it achieved its target operating profit for both the first and second quarters of 2026. For the first quarter, the target was in the 300 billion won range, and for the second quarter, it was in the 400 billion won range.
Expansion into the contract development and manufacturing organization sector is underway. The company established a specialized subsidiary, Celltrion Bio Solutions, in December 2024. To secure production bases in the United States, Celltrion USA Inc. decided to acquire a local company with active pharmaceutical ingredient production facilities in September 2025.
Infrastructure investments continue in South Korea. The company signed a memorandum of understanding in February 2025 to build a drug product plant in Yesan-gun, Chungcheongnam-do, with an investment scale of 300 billion won. A separate investment agreement for a biopharmaceutical and related materials plant in the same region was signed in November 2023, also valued at 300 billion won.
Corporate structure changes included the acquisition of 100% of GIFRER BARBEZAT by Celltrion Healthcare France SAS on June 30, 2026. The company also completed the cancellation of 3,011,910 treasury shares in January 2025.
Looking forward, the company intends to expand its treatment range by continuing research and development into next-generation modalities, such as antibody-drug conjugates and multi-specific antibodies. The company has set a consolidated revenue target of 5.3 trillion won for the full year of 2026.